Flow Cytometry in the Diagnostic Laboratory Workup of Acute Lymphoblastic Leukemias

Keywords

acute lymphoblastic leukemia - flow cytometry - B-ALL - T-ALL

Introduction

Multiparametric flow cytometry is an indispensable tool for the diagnosis and subclassification of acute lymphoblastic leukemia (ALL). Accurate classification of ALLs into B- or T-cell types is crucial for the optimal choice of therapeutic regimens that varies based on the ALL subtype. The antigenic expression profile, particularly the immunophenotypic aberrancies by the blasts deviating from those encountered during normal hematopoiesis, aids in the differentiation of the blasts from their normal benign counterparts. The panel of antigens for clinical testing has evolved from 4 to 13 colors or more thanks to the substantial development in antibody clones, the fluorochrome conjugate options, and a wide variety of lasers that have dramatically increased the number of antigens that can be simultaneously studied. In this article, we attempt to discuss the strategy and approach to the classification of ALL into B- or T-cell subtypes and the evolution of consensus groups for antigen/antibody/fluorochrome selection, choice of reagents, sample processing methodology for appropriate diagnosis, and classification.

B-Acute Lymphoblastic Leukemias

B-lymphoblastic leukemia/lymphoma or B-cell precursor acute lymphoblastic leukemia (BCP-ALL) is the most common malignancy seen in childhood. Approximately 75% of BCP-ALL cases occur in children under 6 years of age.[1] However, it shows a bimodal age distribution, with a small peak occurring during the fifth decade of life.[2] BCP-ALL is diagnosed by morphology combined with immunophenotyping, typically done by multiparametric flow cytometer (MFC). Immunophenotyping is essential for differentiating BCP-ALL from acute leukemias of other lineages, like T-lymphoblastic leukemia (T-ALL), acute myeloid leukemia (AML), mixed phenotype acute leukemia (MPAL), etc.

The flow cytometric diagnosis of BCP-ALL is based on identifying an expanded population of immature B cells showing immunophenotypic aberrancies that help distinguish the leukemic blasts from normal B-cell precursors, or hematogones.[3] These aberrancies are in the form of increased or decreased intensity of expression of an antigen on the leukemic blasts compared to the normal counterparts or gain of antigen expression, which are not specific to B-lineage.[4] Knowledge of the spectrum of antigenic expression on the B-progenitor cells during development is essential to differentiate them from B-leukemic blasts.[5] The normal B-progenitors show the expression of certain antigens in a sequential, tightly regulated manner.[3] The B-progenitor cells are derived from common lymphoid progenitor cells in the bone marrow, and they undergo three stages of maturation to become mature B-lymphoid cells. These three stages of cells are called hematogones type I (early/pre-B-I), hematogones type II (intermediate/pre-B-II), and hematogones type III (late/transitional B-cells).[6] The three stages of hematogones show a stepwise increase in the intensity of expression of CD45 and CD20 while showing a stepwise decrease in intensity of CD34 and CD10, which are finally lost at the late stage. CD19 expression is the lowest in stage I, and increases significantly in stage II, with an eventual mild reduction in mature B cells. Mature B cells show loss of CD34, CD10, and TdT, bright expression of CD20 and CD45, and a surface expression of polytypic immunoglobulins.[5] [Fig. 1] shows flow cytometric dot plots of a BCP-ALL patient.

Fig. 1 Flow cytometric dot plots of a case of BCP-ALL. The blasts (red population) are SSC low, CD45 dim to negative, positive for CD19, CD10, CD34, CD20, CD58, CD123, CD81, CD86, CD38, HLA-DR, CD22, and CytoCD79a. T-cell markers like CD3, CD7, CD5, CD2, CD4, CD8 and NK cell marker like CD56, and, myeloid markers like CD13, CD15, CD33, CD26, CD117, CD14, CD64 and MPO are negative.

The B-leukemic blasts show maturation arrest at any stage and deviation from the normal sequential immunophenotypic maturation kinetics seen in hematogones.[6] [7] [8] Other than this, over- or underexpression of markers like CD123, CD58, CD81, CD86, CD73, CD200, CD9, and CD304 can be seen in the B-leukemic blasts, as shown in [Table 1]. Additionally, they may express aberrant lineage markers like CD13, CD33, CD66c, CD15, CD56, and CD7 that aid in differentiating the B-leukemic blasts from hematogones.[4] [6] [7] [9] [10] [11] [12] [13] [14] [15] [16] [17]

Table 1 Aberrant antigen expression in BCP-ALL compared to hematogones[a]

Antigen	Aberrancy
TdT	Negative/uniform expression
CD34	Negative/uniform expression
CD45	Negative/uniform expression
CD10	Negative/overexpression (uniform bright)
CD20	Uniform expression or negative
CD22	Negative/under expression
CD38	Under expression
CD19	Under/overexpression
CD73	Overexpression
CD58	Overexpression
CD86	Overexpression
CD123	Overexpression
CD200	Overexpression
CD81	Under expression
CD304	Aberrant expression
CD9	Overexpression
CD44	Overexpression
CD13, CD33, CD66c, CD15, CD7, and CD56	Lineage aberrant markers

Abbreviations: BCP-ALL, B-cell precursor acute lymphoblastic leukemia; TdT, terminal deoxynucleotidyl transferase.

^a Please note that all cases of BCP-ALL may not have these aberrancies, and in many cases individual antigens may have expression profile similar to hematogones.

In 1995, the European Group for the Immunological Characterization of Leukemia (EGIL) proposed guidelines for diagnosing and subclassifying BCP-ALL based on immunophenotyping by flow cytometry.[18] According to the EGIL guidelines, B-lineage markers (CD19, CD20, CD22, and CD79a) and immaturity markers (CD34 and TdT) are used to diagnose BCP-ALL. Expression of CD10 and cytoplasmic and surface immunoglobulin M (IgM) are used to subclassify BCP-ALL into four subgroups based on their level of maturation ([Table 2]).

Table 2 EGIL immunophenotypic subclassification of B-ALL

Subclassification	CD10	Cytoplasmic IgM	Surface IgM
B I (pro-B) ALL	Negative	Negative	Negative
B II (pre-pre-B or common B) ALL	Positive	Negative	Negative
B III (pre-B) ALL	Positive	Positive	Negative
B IV (mature B) ALL	Negative/positive	Negative/positive	Positive

Abbreviation: ALL, acute lymphoblastic leukemia; EGIL, European Group for the Immunological Characterization of Leukemia; IgM, immunoglobulin M.

In 2001, the World Health Organization (WHO) introduced a drastic shift in the classification of acute leukemia, including associated genetic abnormalities in the workup for subclassification of BCP-ALL. With an improved understanding of cytogenetic and molecular abnormalities associated with BCP-ALL, and due to their prognostic and therapeutic implications, a complete subtyping and risk stratification of BCP-ALL now require a plethora of molecular tests.

However, since certain specific genetic abnormalities are associated with the expression of particular antigens on the leukemic cells, MFC-based immunophenotyping may provide clues about the genotype[12] and thus help decide which molecular tests to do first.

In 2012, the EuroFlow Consortium put forward guidelines for optimal eight-color antibody panels to diagnose various hematological neoplasms, including BCP-ALL.[8] They initially suggested using an acute leukemia orientation tube (ALOT) for lineage identification ([Table 3]). After confirmation of B-lineage by ALOT tube, further markers for additional characterization are studied in four eight-color tubes. All four tubes contain three backbone markers (CD45, CD19, and CD34) to identify and gate the B-leukemic blasts. The rest of the five antibodies are used to distinguish hematogones from B-leukemic blasts to subclassify the blasts based on their level of maturation, and to identify leukemia-associated immunophenotype (LAIP), which is especially useful in minimal residual disease (MRD) assessment during follow-up. The four-tube eight-color panel recommended by the EuroFlow Consortium for the characterization of B-ALL is shown in [Table 3]. With technological advancements in flow cytometry, 10-colour (and higher) panels are now commonly used for diagnostic purposes. The obvious advantage is that fewer tubes (e.g., single-tube assays) can now be utilized by incorporating a sufficient number of LAIP markers.

Table 3 EuroFlow consortium recommended antibody panel for B-ALL

Tubes	Fluorochromes
	PacB	AmCyan	FITC	PE	PerCPCy5.5	PECy7	APC	AF700
ALOT  Tube	CyCD3	CD45	CyMPO	CyCD79a	CD34	CD19	CD7	SmCD3
BCP-ALL  Tube 1	CD20	CD45	CD58	CD66c	CD34	CD19	CD10	CD38
BCP-ALL  Tube 2	SmIgk	CD45	CyIgμ	CD33	CD34	CD19	SmIgM and CD117	SmIgλ
BCP-ALL  Tube 3	CD9	CD45	NuTdT	CD13	CD34	CD19	CD22	CD24
BCP-ALL  Tube 4	CD21	CD45	CD15 and CD65	NG2	CD34	CD19	CD12 3	CD81

Abbreviations: A-LOT, acute leukemia orientation tube; BCP-ALL, B cell precursor acute lymphoblastic leukemia.

Specific markers have been found to be associated with the BCP-ALL genotype in various studies (highlighted in [Table 4]). The expression of CD66c is positively associated with BCR-ABL1 rearrangement and a few cases of hyperdiploidy. It is rarely seen associated with KMT2A and PBX1 rearrangements.[12] [19] [20] CD13 and CD33 (myeloid markers) are found to be aberrantly expressed in BCR-ABL1 translocated BCP-ALL.[21] The NG2 expression on the surface of B-leukemic blasts is strongly associated with KMT2A rearrangement.[22] [23] Also, KMT2A rearrangement shows loss of CD10 and aberrant expression of CD15.[12] [24]

Table 4 Genotypic associations of a few BCP-ALL antigens detected by MFC

Marker	Genotype association
CD66c	Positively associated with BCR-ABL1 translocation  Rarely seen in KMT2A and PBX1 rearrangement
CD13 and CD33	Positively associated with BCR-ABL1 translocation
CD15, NG2, and loss of CD10	Strongly associated with KMT2A rearrangement
CD9	Positively associated with TCF3::PBX1 rearrangement
CD123	Overexpressed in BCP-ALL with hyperdiploidy  Underexpression associated with ETV6::RUNX1
CRLF2	Positively associated with Ph-like BCP-ALL

Abbreviations: BCP-ALL, B-cell precursor acute lymphoblastic leukemia; MFC, multiparametric flow cytometer.

CD9 is found to be positively associated with the TCF3::PBX1 rearrangement. The TCF3::PBX1 rearranged BCP-ALL also shows a pre-B phenotype with complete loss of CD34, and is positive for cytoplasmic IgM.[23] [25] CD123 is found to be aberrantly overexpressed in BCP-ALL with hyperdiploid karyotype. At the same time, its expression is suppressed in association with the ETV6::RUNX1 rearrangement.[12] [26] Overexpression of the CRLF2 (also known as TSLPR) antigen on the surface of B-leukemic blasts is associated with Ph-like B-ALL, and it is found to be associated with IKZF1 deletion.[27] [28]

Another increasingly important role of flow cytometry in the diagnostic workup of BCP-ALL is the analysis of the ploidy status of the blasts. It is well established that BCP-ALL cases with high hyperdiploidy have better outcomes, while low-hypodiploid and near-haploid patients have poorer outcomes. Although conventional cytogenetics (CC) is the gold standard for ploidy analysis, many studies have shown that flow cytometry–based DNA ploidy analysis correlates well with CC. Various nucleic acid binding dyes (propidium iodide, DAPI, acridine orange, etc.) have been used for this purpose. Recent studies have found that FxCycle Violet is an excellent DNA selective dye excited by the violet laser, which allows simultaneous six- to seven-color immunophenotyping (using blue and red lasers) to separate the blasts from the background normal population and thus accurately assess the ploidy status of the abnormal B-lineage blasts in BCP-ALL.[29] [30]

In recent years, immunotherapy has emerged as another important tool in the treatment of BCP-ALL, and it is often guided by flow cytometric immunophenotyping. A study from MD Anderson Cancer Center showed higher 3-year overall survival with the addition of rituximab (monoclonal antibody [moAb] against CD20) in patients younger than 60 years.[31] Another study showed that the addition of rituximab led to a longer event-free survival and lower frequency of relapses in adult Ph-negative BCP-ALL cases.[32] Both these studies used rituximab in patients whose blasts showed at least 20% CD20 expression. Ofatumumab, another anti-CD20 moAb, has been used with good results in patients in whom CD20 expression was as low as 1%.[33]

CD19 is expressed ubiquitously in BCP-ALL. Immunotherapy targeting CD19, in the form of bispecific T-cell engager (BiTE) called band anti-CD19 chimeric antigen receptor T cells (CARTs), has emerged as a promising agent in relapsed refractory BCP-ALL. CD19-negative blasts have been described in relapses following treatment with Blinatumomab and CART, and pose a challenge to their detection using MFC. CD22 is also expressed in a vast majority of BCP-ALL, and Inotuzumab ozogamicin (directed against CD22) has also shown good results in refractory BCP-ALL.[34]

T-Acute Lymphoblastic Leukemia

T-acute lymphoblastic leukemias (T-ALLs) account for approximately 15% of the pediatric ALLs and 25% of the adult ALL groups.[35] T-ALLs are defined by surface or cytoplasmic CD3 (CyCD3) expression. The markers of the T-cell lineage are CD1a, CD2, CD3, CD4, CD5, CD7, and CD8. CD7 expression is usually bright and uniform in patients with T-ALL. CD7 is highly sensitive for T-ALL; however, it is nonspecific as it is also aberrantly frequently expressed in blasts of AML.[36] The expression of other markers like CD1a, CD2, CD3 (surface membrane [Sm]), CD4, CD5, and CD8 is variable depending on the maturational stage of the blasts.[37] Markers like CD2, CD5, and CD7 correspond to most immature T cells; however, they lack lineage specificity. CyCD3 is a marker constantly expressed by T-ALLs and is lineage specific with no cross-reactivity, appearing at the early stages of maturation. A combination of CyCD3 and SmCD3 is helpful as it identifies a CyCD3⁺/SmCD3^–/dim population, most frequently observed in patients of T-ALL.[8] Using anti-CD3 epsilon chain antibody is important and as per available literature, the CD3 clone S4.1 gives increased autofluorescence, whereas UCHT-1-PE gives the highest specific fluorescence intensity for intracellular staining.[38] [39]

Maturation abnormalities observed in T-ALLs serve to differentiate abnormal T-lymphoblasts from normal thymic cells. According to the degree of thymic differentiation, the EGIL classified T-ALLs into four major subgroups.[18] These subgroups included pro-T-ALL (T-1), pre-T-ALL (T-2), cortical T-ALL (T-3), and medullary T-ALL (T-4; [Table 5]). Immature T-ALLs, CD1^–/CD7⁺, constitute the pro-T-ALLs, and those expressing CD2 and CD5 represent the pre-T-ALL subtype. Cases positive for CD1 and frequently dual positive for CD4/CD8 form the cortical type, and the ones with SmCD3⁺/CD1^– form the mature T-ALL subgroup. Flow cytometry data from a patient with T-ALL are shown in [Fig. 2]. Further, based on the expression of SmCD3 and the type of T-cell receptor, T-ALLs can be classified as SmCD3⁺/TCR-ab⁺ and SmCD3⁺/TCR-gd⁺ subgroups.

Fig. 2 Flow cytometric dot plots of a case of T-ALL. The blasts (red population) are SSC low and CD45 dim, positive forcytoCD3, CD2, CD5, smCD3, CD7, CD4, CD8, and negative for CD1a, TCRab, TCRgd, and nuTdT. The blasts are negative for B-cell and myeloid markers.

Table 5 EGIL classification of T-ALL

Markers	Pro-T-ALL	Pre-T-ALL	Cortical T-ALL	Medullary T-ALL
CD1	–	–	+ +	–
CD2	+	+ +	+ +	+ +
SmCD3	–	–	– (except in SmCD3+ subtypes, ++)	+ +
CyCD3	+ +	+ +	+ +	+ +
CD4–/CD8–	+ +	+	–	–
CD4–/CD8+	–	±	±	±
CD4+/CD8–	–	±	±	+
CD4+/CD8+	–	–	+	±
CD5	–	+ +	+ +	+ +
CD7	+ +	+ +	+ +	+ +

Abbreviations: EGIL, European Group for the Immunological Characterization of Leukemia; T-ALL, T acute lymphoblastic leukemia.

Note: –, positive in <10% of the T-ALLs; ± , positive in 10–25% of the T-ALLs; +, 25–75% of the T-ALLs are positive; ++, positive in >75% of the T-ALLs.

CD45, the pan-leukocyte gating marker, is often expressed brighter in T-ALLs than B-ALLs, and the expression level might significantly overlap with mature lymphocytes.[37] Other markers indicating an immature phenotype include CD34 and terminal deoxynucleotidyl transferase (TdT), which are positive in a proportion of T-ALL patients. CD10 (common acute lymphoblastic leukemia antigen [CALLA]) is positive in some patients (10% of all T-ALLs), but it seldom carries any diagnostic significance in classifying T-ALLs. CyCD79a, a marker associated with B-cell lineage, can be expressed at low levels in a fraction of T-ALLs, particularly the TCRgd⁺ subgroup.[40] Expression of myeloid-associated markers such as CD13, CD33, and CD117 is found in some cases of T-ALL, especially in the recently described category of early T-cell precursor T-ALL (ETPALL).

ETPALL is a recently described category of immature T-ALLs (∼15% of the cases) with low response rates to chemotherapy and dismal prognosis.[41] It is characterized by the absence of CD1a and CD8. CD5 is found weakly expressed (negative or dim, in <75% of the blast population) along with the expression of myeloid/stem cell–associated antigens (in at least >25% of the blast population) such as CD34, HLA-DR, CD13, CD33, CD11b, CD65, and CD117. Scoring systems incorporating a 6- or an 11-marker panel are used to identify patients of ETPALL. The expression of CD5 in patients with ETPALL is heterogeneous, and cases exhibiting a strong positivity for CD5 were further classified as near-ETPALL.[42]

The EuroFlow Consortium, in 2012,[8] designed an antibody panel for the diagnosis and immunophenotypic characterization of T-ALLs. This antibody panel was run when the ALOT tube suggested T-lineage blast proliferation. The panel was set with a combination of markers aimed at the identification of the blasts (cyCD3, CD45, and smCD3), markers for the differential diagnosis of T-ALL, and to specify the maturational stage of the blasts for subclassification of T-ALL with markers such as CD1a, CD2, CD3, CD4, CD5, CD7, CD8, CD10, TCR-ab, and TCR-gd. CD1a, CD34, CD99, and nuTdT were included to indicate the precursor nature of the blasts. Additional markers, including CD44, CD45RA, and CD123, were also used, which contribute to maturational staging.[8] [43] [44] [45] Myeloid antigens such as CD13, CD33, and CD117 were added to the panel to identify cases with early precursor T-cell immunophenotype. [Table 6] shows the T-ALL panel designed by the EuroFlow Consortium.

Table 6 EuroFlow consortium recommended eight color antibody panels for T-ALL

T-ALL tubes	Fluorochromes
	PacB	AmCyan	FITC	PE	PerCPCy5.5	PECy7	APC	AF700
Tube 1	CyCD3	CD45	NuTdT	CD99	CD5	CD10	CD1a	SmCD3
Tube 2	CyCD3	CD45	CD2	CD117	CD4	CD8	CD7	SmCD3
Tube 3	CyCD3	CD45	TCRgd	TCRab	CD33	CD56	CyTCRb	SmCD3
Tube 4	CyCD3	CD45	CD44	CD13	HLADR	CD45RA	CD123	SmCD3

Abbreviation: T-ALL, T-acute lymphoblastic leukemia.

T-ALL, especially the ETPALL, can be confused with MPAL (T/myeloid type). A combination of markers like CD3, CD7, and myeloperoxidase must be used for accurate lineage identification. The recent update on the classification of myeloid and histiocytic/dendritic cell neoplasm has redefined the lineage assignment criteria for the diagnosis of MPAL.[46] CD3 expression (cytoplasmic or surface), with an expression intensity exceeding 50% of the mature T-lymphocytes on flow cytometry, is recommended for the assignment of T-lineage. Similarly, for myeloid lineage, myeloperoxidase expression intensity in part exceeds greater than 50% of the neutrophil level or expression of two or more WHO-defined markers of monocytic differentiation.[46]

Finally, information on the certain antigens expressed by the leukemic blasts can guide for targeted immunotherapies in T-ALL.[47] A lot of clinical trials have proved the efficiency of moAbs against specific antigens, particularly in relapsed/refractory T-ALLs. MoAbs to CD38 (daratumumab) and CD52 (alemtuzumab) have been tried in T-ALL patients and several new antigens such as CXCR4, IL7R, CD30, CD43, CD44, CD99, and CD194 are investigated as potential new targets for immunotherapy in T-ALL patients.[47] [48] These antibodies can be utilized in the diagnostic panel of antibodies if clinical settings for immunotherapies are available.

Conclusion

To summarize, immunophenotyping by flow cytometry is an essential component in the diagnosis of ALL and distinguishing it as B- or T-ALL and from other leukemias such as AML and MPAL. A suitable panel of antigens needs to be analyzed for improved sensitivity and specificity of the test. Flow cytometric immunophenotype at baseline is essential to identify the antigenic aberrancy in the leukemic blasts, which aids in minimal/measurable disease (MRD) assessment at follow-up and to differentiate residual leukemic blasts from their normal counterparts.

• References

• 1 Gujral S, Badrinath Y, Kumar A. et al. Immunophenotypic profile of acute leukemia: critical analysis and insights gained at a tertiary care center in India. Cytometry B Clin Cytom 2009; 76 (03) 199-205
• 2 Paul S, Kantarjian H, Jabbour EJ. Adult acute lymphoblastic leukemia. Mayo Clin Proc 2016; 91 (11) 1645-1666
• 3 Wood BL. Flow cytometry in the diagnosis and monitoring of acute leukemia in children. J Hematop 2015; 8: 191-199
• 4 Rezaei MS, Esfandiari N, Refoua S, Shamaei M. Characterization of immunophenotypic aberrancies in adult and childhood acute lymphoblastic leukemia: lessons from regional variation. Iran J Pathol 2020; 15 (01) 1-7
• 5 DiGiuseppe JA. . Acute lymphoblastic leukemia/lymphoma: diagnosis and minimal residual disease detection by flow cytometric immunophenotyping. In: Detrick B, Schmitz JL, Hamilton RG, eds. Manual of Molecular and Clinical Laboratory Immunology. Washington, DC: ASM Press; 2016
• 6 Sędek Ł, Bulsa J, Sonsala A. et al. The immunophenotypes of blast cells in B-cell precursor acute lymphoblastic leukemia: how different are they from their normal counterparts?. Cytometry B Clin Cytom 2014; 86 (04) 329-339
• 7 McKenna RW, Washington LT, Aquino DB, Picker LJ, Kroft SH. Immunophenotypic analysis of hematogones (B-lymphocyte precursors) in 662 consecutive bone marrow specimens by 4-color flow cytometry. Blood 2001; 98 (08) 2498-2507
• 8 van Dongen JJM, Lhermitte L, Böttcher S. et al; EuroFlow Consortium (EU-FP6, LSHB-CT-2006-018708). EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia 2012; 26 (09) 1908-1975
• 9 Thalhammer-Scherrer R, Mitterbauer G, Simonitsch I. et al. The immunophenotype of 325 adult acute leukemias: relationship to morphologic and molecular classification and proposal for a minimal screening program highly predictive for lineage discrimination. Am J Clin Pathol 2002; 117 (03) 380-389
• 10 Seegmiller AC, Kroft SH, Karandikar NJ, McKenna RW. Characterization of immunophenotypic aberrancies in 200 cases of B acute lymphoblastic leukemia. Am J Clin Pathol 2009; 132 (06) 940-949
• 11 Gupta M, Monga L, Mehrotra D, Chhabra S, Singhal S, Sen R. Immunophenotypic aberrancies in acute leukemia: a tertiary care centre experience. Oman Med J 2021; 36 (01) e218-e218
• 12 Kulis J, Sędek Ł, Słota Ł, Perkowski B, Szczepański T. Commonly assessed markers in childhood BCP-ALL diagnostic panels and their association with genetic aberrations and outcome prediction. Genes (Basel) 2022; 13 (08) 1374
• 13 Chernysheva O, Grivtsova LY, Popa A, Tupitsyn NN. . B-cell precursors: immunophenotypic features in the detection of minimal residual disease in acute leukemia. In: Aribi M, ed. Normal and Malignant B-Cell [Internet]. IntechOpen; 2020. Accessed June 20, 2022 at: https://www.intechopen.com/books/normal-and-malignant-b-cell/b-cell-precursors-immunophenotypic-features-in-the-detection-of-minimal-residual-disease-in-acute-le
• 14 Solly F, Angelot F, Garand R. et al. CD304 is preferentially expressed on a subset of B-lineage acute lymphoblastic leukemia and represents a novel marker for minimal residual disease detection by flow cytometry. Cytometry A 2012; 81 (01) 17-24
• 15 Sherif L, Azab M, Al-Akad G, Zakaria M, Atfy M, Sorour S. Cluster of differentiation 97 as a biomarker for the detection of minimal residual disease in common acute lymphoblastic leukemia. Egypt J Haematol. 2017; 42: 81-87
• 16 Kamazani FM, Bahoush GR, Aghaeipour M, Vaeli S, Amirghofran Z. CD44 and CD27 expression pattern in B cell precursor acute lymphoblastic leukemia and its clinical significance. Med Oncol 2013; 30 (01) 359
• 17 DiGiuseppe JA, Fuller SG, Borowitz MJ. Overexpression of CD49f in precursor B-cell acute lymphoblastic leukemia: potential usefulness in minimal residual disease detection. Cytometry B Clin Cytom 2009; 76 (02) 150-155
• 18 Bene MC, Castoldi G, Knapp W. et al; European Group for the Immunological Characterization of Leukemias (EGIL). Proposals for the immunological classification of acute leukemias. Leukemia 1995; 9 (10) 1783-1786
• 19 Guillaume N, Penther D, Vaida I. et al. CD66c expression in B-cell acute lymphoblastic leukemia: strength and weakness. Int J Lab Hematol 2011; 33 (01) 92-96
• 20 Owaidah TM, Rawas FI, Al Khayatt MF, Elkum NB. Expression of CD66c and CD25 in acute lymphoblastic leukemia as a predictor of the presence of BCR/ABL rearrangement. Hematol Oncol Stem Cell Ther 2008; 1 (01) 34-37
• 21 Suggs JL, Cruse JM, Lewis RE. Aberrant myeloid marker expression in precursor B-cell and T-cell leukemias. Exp Mol Pathol 2007; 83 (03) 471-473
• 22 Kulis J, Wawrowski Ł, Sędek Ł. et al. Machine learning based analysis of relations between antigen expression and genetic aberrations in childhood B-cell precursor acute lymphoblastic leukaemia. J Clin Med 2022; 11 (09) 2281
• 23 Hrusák O, Porwit-MacDonald A. Antigen expression patterns reflecting genotype of acute leukemias. Leukemia 2002; 16 (07) 1233-1258
• 24 Schwartz S, Rieder H, Schläger B, Burmeister T, Fischer L, Thiel E. Expression of the human homologue of rat NG2 in adult acute lymphoblastic leukemia: close association with MLL rearrangement and a CD10(-)/CD24(-)/CD65s(+)/CD15(+) B-cell phenotype. Leukemia 2003; 17 (08) 1589-1595
• 25 Tsagarakis NJ, Papadhimitriou SI, Pavlidis D. et al. Flow cytometric predictive scoring systems for common fusions ETV6/RUNX1, BCR/ABL1, TCF3/PBX1 and rearrangements of the KMT2A gene, proposed for the initial cytogenetic approach in cases of B-acute lymphoblastic leukemia. Int J Lab Hematol 2019; 41 (03) 364-372
• 26 Djokic M, Björklund E, Blennow E, Mazur J, Söderhäll S, Porwit A. Overexpression of CD123 correlates with the hyperdiploid genotype in acute lymphoblastic leukemia. Haematologica 2009; 94 (07) 1016-1019
• 27 Vetter T, Borowski A, Wohlmann A. et al. Blockade of thymic stromal lymphopoietin (TSLP) receptor inhibits TSLP-driven proliferation and signalling in lymphoblasts from a subset of B-precursor ALL patients. Leuk Res 2016; 40: 38-43
• 28 Pastorczak A, Sedek L, Braun M. et al. Surface expression of cytokine receptor-like factor 2 increases risk of relapse in pediatric acute lymphoblastic leukemia patients harboring IKZF1 deletions. Oncotarget 2018; 9 (40) 25971-25982
• 29 Tembhare P, Badrinath Y, Ghogale S. et al. A novel and easy FxCycle™ violet based flow cytometric method for simultaneous assessment of DNA ploidy and six-color immunophenotyping. Cytometry A 2016; 89 (03) 281-291
• 30 Gupta N, Parihar M, Banerjee S. et al. FxCycle™ based ploidy correlates with cytogenetic ploidy in B-cell acute lymphoblastic leukemia and is able to detect the aneuploid minimal residual disease clone. Cytometry B Clin Cytom 2019; 96 (05) 359-367
• 31 Thomas DA, O'Brien S, Faderl S. et al. Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia. J Clin Oncol 2010; 28 (24) 3880-3889
• 32 Maury S, Chevret S, Thomas X. et al; for GRAALL. Rituximab in B-lineage adult acute lymphoblastic leukemia. N Engl J Med 2016; 375 (11) 1044-1053
• 33 Jabbour E, Richard-Carpentier G, Sasaki Y. et al. Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial. Lancet Haematol 2020; 7 (07) e523-e533
• 34 Jasinski S, De Los Reyes FA, Yametti GC, Pierro J, Raetz E, Carroll WL. Immunotherapy in pediatric B-cell acute lymphoblastic leukemia: advances and ongoing challenges. Paediatr Drugs 2020; 22 (05) 485-499
• 35 Guru Murthy GS, Pondaiah SK, Abedin S, Atallah E. Incidence and survival of T-cell acute lymphoblastic leukemia in the United States. Leuk Lymphoma 2019; 60 (05) 1171-1178
• 36 Craig FE, Foon KA. Flow cytometric immunophenotyping for hematologic neoplasms. Blood 2008; 111 (08) 3941-3967
• 37 DiGiuseppe JA, Wood BL. Applications of flow cytometric immunophenotyping in the diagnosis and posttreatment monitoring of B and T lymphoblastic leukemia/lymphoma. Cytometry B Clin Cytom 2019; 96 (04) 256-265
• 38 van Dongen JJ, Krissansen GW, Wolvers-Tettero IL. et al. Cytoplasmic expression of the CD3 antigen as a diagnostic marker for immature T-cell malignancies. Blood 1988; 71 (03) 603-612
• 39 Gujral S, Tembhare P, Badrinath Y, Subramanian PG, Kumar A, Sehgal K. Intracytoplasmic antigen study by flow cytometry in hematolymphoid neoplasm. Indian J Pathol Microbiol 2009; 52 (02) 135-144
• 40 Hashimoto M, Yamashita Y, Mori N. Immunohistochemical detection of CD79a expression in precursor T cell lymphoblastic lymphoma/leukaemias. J Pathol 2002; 197 (03) 341-347
• 41 Coustan-Smith E, Mullighan CG, Onciu M. et al. Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol 2009; 10 (02) 147-156
• 42 Sin CF, Man PM. Early T-cell precursor acute lymphoblastic leukemia: diagnosis, updates in molecular pathogenesis, management, and novel therapies. Front Oncol 2021; 11: 750789
• 43 Falcão RP, Garcia AB. Expression of CD45RA (naive) and CD45RO (memory) antigens in T-acute lymphoblastic leukaemia. Br J Haematol 1993; 85 (03) 483-486
• 44 Cavalcanti Júnior GB, Savino W, Pombo-de-Oliveira MS. CD44 expression in T-cell lymphoblastic leukemia. Braz J Med Biol Res 1994; 27 (09) 2259-2266
• 45 Lhermitte L, de Labarthe A, Dupret C. et al. Most immature T-ALLs express Ra-IL3 (CD123): possible target for DT-IL3 therapy. Leukemia 2006; 20 (10) 1908-1910
• 46 Khoury JD, Solary E, Abla O. et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia 2022; 36: 1703-1719
• 47 Bayón-Calderón F, Toribio ML, González-García S. Facts and challenges in immunotherapy for T-cell acute lymphoblastic leukemia. Int J Mol Sci 2020; 21 (20) 7685
• 48 Caracciolo D, Mancuso A, Polerà N. et al. The emerging scenario of immunotherapy for T-cell acute lymphoblastic leukemia: advances, challenges and future perspectives. Exp Hematol Oncol 2023; 12 (01) 5